The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series
Open Access
- 13 June 2011
- journal article
- case report
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2011, 1-5
Abstract
Anal cancer patients who have exhibited disease progression after having received all approved drugs pose a major therapeutic challenge. In addition to cytotoxic agents, novel targeted agents are being developed and have an established role in the treatment of many solid tumors, including colon cancer. However, their role in anal cancer is yet to be determined. Most anal malignancies are squamous cell carcinomas often strongly expressing epidermal growth factor receptors (EGFRs). Targeting the latter seems to result in favorable changes in tumor growth. We present three cases of refractory anal cancers, treated with EGFR inhibitors, after having received the recommended chemotherapy regimens. We conclude that EGFR inhibitors may play a vital role in the treatment of anal cancer and we suggest that large trials are be conducted in order to clarify their efficacy and to improve therapeutic management.Keywords
This publication has 28 references indexed in Scilit:
- Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomasBMC Cancer, 2010
- Integration of panitumumab into the treatment of colorectal cancerCritical Reviews in Oncology/Hematology, 2010
- Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational StatusOncology, 2009
- Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virusHuman Pathology, 2009
- Epidermal Growth Factor Receptor Inhibitors: Current Status and Future DirectionsCurrent Problems in Cancer, 2009
- Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In VivoAnnals of Surgical Oncology, 2009
- Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a CaseDiseases of the Colon & Rectum, 2007
- Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin CBiochemical and Biophysical Research Communications, 2006
- Metastatic Anal Cancer: The Search for CureOncology Research and Treatment, 2006
- Epidermal Growth Factor Receptor Expression in Anal Canal CarcinomaAmerican Journal of Clinical Pathology, 2005